# Allergy Therapeutics “2022 is going to be a pivotal year”

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-2022-is-going-to-be-a-pivotal-year/4121043133
- Published: 2022-01-13T07:18:43+00:00
- Author: Amilia Stone

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology company specialising in allergy vaccines,
has provided a trading update for the six months ended 31 December 2021 ahead of
its Half Year Results to be announced on 3 March 2022.

–     _VLP Peanut IND application submitted to FDA with a protocol enabling Phase
I  trial (named PROTECT); expected results in H1 2023 ahead of original Q4 2023 
data readout_

–     _IMP VLP Peanut batch manufactured and ready for start of upcoming PROTECT
trial_

–     _Strategic streamlining of products to focus on SCIT and innovative allergy
treatments_

–     _Strong cash position to support Grass MATA MPL pivotal Phase III field studies
and Phase I VLP Peanut PROTECT trial_

–     _Phase III Grass MATA MPL trial on track to start Q3 2022 following impressive
results from exploratory field trial_

**Financials**

Reported revenues for the six months ended 31 December 2021 are expected to be £
48.7m (2020: £54.0m), representing a 10% reduction on a reported basis (down 5% 
on constant currency basis). This  is primarily due to the previously disclosed 
strategic streamlining of non-differentiated older products to maintain focus on
short course subcutaneous immunotherapy (SCIT) and innovative allergy treatments.
On this revised basis revenues have increased 3% on a like for like product and 
phasing basis (on constant currency basis).

Revenues were also affected by phasing, headwinds in Germany and the continuing 
effect of COVID-19 in Italy and Germany. However Spain, the Group’s second most 
important market, saw a double-digit growth in sales, while the Netherlands, UK 
and Rest of World (RoW) also grew strongly. There was double-digit growth for key
products Pollinex, Venomil and Acarovac (on constant currency basis).

Reported revenue for the year is likely to be down on the 2021 financial year by
an upper single digit percentage, but through planned cost reductions in the second
half of the year, the Board remains confident that market consensus for the operating
profit pre R&D this financial year will be achieved.

Allergy Therapeutics has continued to generate good cash conversion, with a strong
cash balance at the end of December 2021 of £41.4m (31 December 2020: £48.3m).

On current internal assumptions and as previously communicated, the Group will be
able to fund the Grass MATA MPL Phase III trial (G306), as well as the VLP Peanut
Phase I PROTECT trial, from existing resources with a small amount of additional
debt.

**Regulatory**

The Group has successfully submitted the Investigational New Drug (IND) application
for VLP Peanut to the US Food and Drug Administration (FDA). Following consultation
with experts in the field, the IND application includes a protocol for the upcoming
Phase I PROTECT trial, moving the planned paediatric and adolescent arms into a 
future Phase II trial. As a result, topline data from the Phase I PROTECT trial,
in adult patients, would be anticipated in H1 2023, ahead of the original intended
Q4 2023 data readout.

Furthermore, the batch of investigational medicinal product (IMP) intended for use
in the upcoming Phase I PROTECT trial has been successfully manufactured, tested
and released. This product aims to revolutionise the peanut allergy market as a 
treatment that has the potential to provoke a disease-modifying effect and to bring
a significant positive impact to the lives of patients and families affected by 
peanut allergy, and to health systems. The market for peanut allergies is expected
to be around $8bn worldwide.

Following the outcome of the Grass MATA MPL exploratory field trial in October 2021
which showed efficacy of 36.8% in an extended posology, the Group is now on track
to begin the Grass MATA MPL pivotal Phase III trial (G306) in the autumn of this
calendar year.

> **Manuel Llobet, CEO at Allergy Therapeutics, stated:** “2022 is going to be a
> pivotal year for Allergy Therapeutics with the VLP Peanut Phase I PROTECT trial
> and MATA MPL Phase III trial (G306) commencing during the calendar year. We continue
> to be very encouraged by the data and the clinical progress supporting these highly
> innovative product trials. The Group has continued to perform and I am encouraged
> by our response to the challenges from what continues to be a tough environment.
> Our focus on providing innovative allergy treatments to patients in need, as well
> as delivering a strong, differentiated R&D pipeline remains key to our strategy.
> We are confident in the Group’s commercial capabilities despite being cautious
> due to COVID-related uncertainties and we look forward to reporting the significant
> progress expected in our clinical pipeline.”

Share on:
